Target molecules for future hidradenitis suppurativa treatment.
biomarkers
hidradenitis suppurativa
treatment targets
Journal
Experimental dermatology
ISSN: 1600-0625
Titre abrégé: Exp Dermatol
Pays: Denmark
ID NLM: 9301549
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
14
03
2021
accepted:
18
03
2021
entrez:
4
6
2021
pubmed:
5
6
2021
medline:
25
3
2022
Statut:
ppublish
Résumé
The registration of the tumour necrosis factor-α inhibitor adalimumab in 2015 was a major step forward in the treatment of hidradenitis suppurativa/acne inversa (HS). However, it soon became evident that the effectiveness of adalimumab in daily practice was highly variable. A significant unmet medical need of HS patients remained, and the search for novel therapeutic targets was intensified. During the 10th European Hidradenitis Suppurativa Foundation (EHSF) e.V. Conference, reknown international HS investigators virtually presented and discussed the published data on these potential target molecules for future HS treatment. This article addresses the most promising molecules currently under investigation from a pathophysiological and clinical point of view. With phase III trials ongoing, the anti- interleukin (IL)-17 biologics bimekizumab and secukinumab are in the most advanced stage of clinical development showing promising results. In addition, targeting IL-1α with bermekimab has shown encouraging results in two clinical trials. Directing treatment at neutrophil recruitment and activation by targeting IL-36 with spesolimab fits well in the pathogenic concept of HS and clinical phase II trial results are pending. In contrast to in situ evidence, Complement 5a (C5a) and C5a receptor blockade have only shown greater clinical benefit in patients with severe HS. Inhibition of Janus kinase (JAK) 1 signalling in HS showed clinical efficacy only in the highest dosage, highlighting that careful surveillance of the balance between safety and efficacy of JAK inhibition is warranted. Overall, clinical efficacies of all novel treatments reported so far are modest. To guide drug development, more and better-defined translational data on the pathogenesis of this severe and enigmatic inflammatory skin disease are required.
Substances chimiques
IL17A protein, human
0
Immunologic Factors
0
Interleukin-17
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
8-17Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Zouboulis CC, Benhadou F, Byrd A, et al. What causes hidradenitis suppurativa? 15 years after. Exp Dermatol. 2020;29:1154-1170.
https://clinicaltrials.gov/ct2/results?recrs=&cond=Hidradenitis+Suppurativa&term=&cntry=&state=&city=&dist= (website accessed March 4, 2021).
Vossen ARJV, Ardon CB, van der Zee HH, Lubberts E, Prens EP. The anti-inflammatory potency of biologics targeting tumour necrosis factor-a, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study. Br J Dermatol. 2019;181:314-323.
Zouboulis CC. Ex vivo human models of hidradenitis suppurativa / acne inversa for laboratory research and drug screening. Br J Dermatol. 2019;181:244-246.
Zouboulis CC, Nogueira da Costa A, Makrantonaki E, et al. Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2020;34:846-861.
Zouboulis CC, Nogueira da Costa A, Fimmel A, Zouboulis KC. Apocrine glands are bystanders in hidradenitis suppurativa and their involvement is gender-specific. J Eur Acad Dermatol Venereol. 2020;34:1555-1563.
Zouboulis CC, Nogueira da Costa A. Drug repurposing through drug-gene interaction profiles for hidradenitis suppurativa/acne inversa treatment. J Eur Acad Dermatol Venereol. 2021;35:e251-e254.
Zouboulis CC, Readhead B, Dudley JT. An additional drug repurposing study for hidradenitis suppurativa/acne inversa. Br J Dermatol. 2021;184:748-750.
Byrd AS, Dina Y, Okoh UJ, et al. Specimen collection for translational studies in hidradenitis suppurativa. Sci Rep. 2019;9:12207.
Tricarico P, Boniotto M, Genovese G, Zouboulis CC, Marzano AV, Crovella S. Skin-OMICS: an integrated approach to unravel hidradenitis suppurativa etiopathogenesis. Front Immunol. 2019;10:892.
Frew JM, Hawkes JE, Sullivan-Whalen M, Gilleaudeau P, Krueger JG. Inter-rater reliability of phenotypes and exploratory genotype-phenotype analysis in inherited hidradenitis suppurativa. Br J Dermatol. 2019;181:566-571.
Jenei A, Dajnoki Z, Medgyesi B, et al. Apocrine gland-rich skin has a non-inflammatory IL-17 related immune milieu, which turns to inflammatory IL-17 mediated disease in hidradenitis suppurativa. J Invest Dermatol. 2019;139:964-968.
Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized controlled trial. JAMA Dermatol. 2016;152:52-59.
Kanni T, Argyropoulou M, Spyridopoulos T, et al. MABp1 targeting IL-1α for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study. J Invest Dermatol. 2018;138:795-801.
Gottlieb A, Natsis NE, Kerdel F, et al. A phase II open-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain. J Invest Dermatol. 2020;140(8):1538-1545.
Kanni T, Argyropoulou M, Dinarello CA, Simard J, Giamarellos-Bourboulis EJ. MABp1 targeting interleukin-1α in hidradenitis supurativa ineligible for adalimumab treatment: results of the open-label extension period. Clin Exp Dermatol. 2021;46:162-163.
Schlapbach C, Hänni T, Yawalkar N, Hunger RE. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65:790-798.
Wolk K, Warszawska K, Hoeflich C, et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol. 2011;186:1228-1239.
Kelly G, Hughes R, McGarry T, et al. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol. 2015;173:1431-1439.
Moran B, Sweeney CM, Hughes R, et al. Hidradenitis suppurativa is characterized by dysregulation of the Th17: Treg cell axis, which is corrected by anti-TNF therapy. J Invest Dermatol. 2017;137:2389-2395.
Fletcher JM, Moran B, Petrasca A, Smith CM. IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa. Clin Exp Immunol. 2020;201:121-134.
Navrazhina K, Frew JW, Krueger JG. Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa. Br J Dermatol. 2020;182:1045-1047.
Thorlacius L, Theut Riis P, Jemec GBE. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol. 2018;179:182-185.
Casseres RG, Prussick L, Zancanaro P, et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol. 2020;82:1524-1526.
Frew JW, Navrazhina K, Grand D, et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study. J Am Acad Dermatol. 2020;83:1341-1348.
Ribero S, Ramondetta A, Fabbrocini G, et al. Effectiveness of secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting. J Eur Acad Dermatol Venereol. 2021. https://doi.org/10.1111/jdv.17178
Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of IHS4, a novel dynamic scoring system to assess hidradenitis suppurativa/acne inversa severity. Br J Dermatol. 2017;177:1401-1409.
Martínez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis. 2001;7:323-326.
von Laffert M, Helmbold P, Wohlrab J, Fiedler E, Stadie V, Marsch WC. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol. 2010;19:533-537.
Kjaersgaard Andersen R, Saunte SK, Jemec GBE, Saunte DM. Psoriasis as a comorbidity of hidradenitis suppurativa. Int J Dermatol. 2020;59:216-220.
Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278:1910-1914.
Towne JE, Sims JE. IL-36 in psoriasis. Curr Opin Pharmacol. 2012;12:486-490.
Di Caprio R, Balato A, Caiazzo G, et al. IL-36 cytokines are increased in acne and hidradenitis suppurativa. Arch Dermatol Res. 2017;309:673-678.
Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN. The molecular regulation of Janus kinase (JAK) activation. Biochem J. 2014;462:1-13.
Zhou YJ, Magnuson KS, Cheng TP, et al. Hierarchy of protein tyrosine kinases in interleukin-2 (IL-2) signaling: activation of syk depends on Jak3; however, neither Syk nor Lck is required for IL-2-mediated STAT activation. Mol Cell Biol. 2000;20:4371-4380.
Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76:736-744.
Works MG, Yin F, Yin CC, et al. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis. J Immunol. 2014;193:3278-3287.
Navrazhina K, Frew JW, Gilleaudeau P, Sullivan-Whalen M, Garcet S, Krueger JG. Epithelialized tunnels are a source of inflamamtion in hidradenitis suppurativa. J Allerg Clin Immunol. 2021. https://doi.org/10.1016/j.jaci.2020.12.651
Byrd AS, Carmona-Rivera C, O'Neil LJ, et al. Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa. Sci Transl Med. 2019;11(508):eaav5908.
Ponikowska M, Matusiak L, Kasztura M, Jankowska EA, Szepietowski JC. Deranged iron status evidenced by iron deficiency characterises patients with hidradenitis suppurativa. Dermatology. 2020;236:52-58.
Frew JW, Marzano AV, Wolk K, et al. A systematic review of promoting therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance. J Invest Dermatol. 2021;141:316-324.
Savage K, Santillian MR, Flood KS, Charrow A, Porter ML, Kimball AB. Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa. JAAD Case Rep. 2020;6:99-102.
A placebo-controlled study of the safety of INCB054707 in participants with hidradenitis suppurativa (NCT03607487). ClinicalTrials.gov Website. Accessed July 31, 2020.
A study of oral upadacitinib tablet compared to placebo in adult participants with moderate to severe hidradenitis suppurativa to assess change in disease symptoms (NCT04430855). ClinicalTrials.gov (website accessed July 31, 2020).
Topical ruxolitinib 1.5% for HS (NCT04414514). ClinicalTrials.gov (website accessed July 31, 2020).
Tofacitinib for immune skin conditions in Down syndrome (NCT04246372). ClinicalTrials.gov (website accessed July 31, 2020).
Bresnick AR. S100 proteins as therapeutic targets. Biophys Rev. 2018;10:1617-1629.
Wolf R, Mirmohammadsadegh A, Walz M, et al. Molecular cloning and characterization of alternatively spliced mRNA isoforms from psoriatic skin encoding a novel member of the S100 family. FASEB J. 2003;17:1969-1971.
Wolk K, Join-Lambert O, Sabat R. Aetiology and pathogenesis of hidradenitis suppurativa. Br J Dermatol. 2020;183:999-1010.
Marzano AV, Damiani G, Ceccherini I, Berti E, Gattorno M, Cugno M. Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis). Br J Dermatol. 2017;176:1588-1598.
Lowe MM, Naik HB, Clancy S, et al. Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-α therapy. JCI Insight. 2020;5:e139932.
Gay NJ, Gangloff M, O'Neill LA. What the myddosome structure tells us about the initiation of innate immunity. Trends Immunol. 2011;32:104-109.
Mullard A. IRAK4 degrader to take on innate immunity. Nat Biotechnol. 2020;38:1221-1223.
Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821-852.
Frew JW. Complement, hidradenitis suppurativa and pathogen-driven positive selection. Br J Dermatol. 2019;180:685-686.
Ghias MH, Hyde MJ, Tomalin LE, et al. Role of the complement pathway in inflammatory skin diseases: a focus on hidradenitis suppurativa. J Invest Dermatol. 2020;140(3):531-536.
Grand D, Navrazhina K, Frew JW. Integrating complement into the molecular pathogenesis of hidradenitis suppurativa. Exp Dermatol. 2020;29:86-92.
Ort M, Dingemanse J, van den Anker J, Kaufmann P. Treatment of rare inflammatory kidney diseases: drugs targeting the terminal complement pathway. Front Immunol. 2020;11:599417.
Hoffman LK, Tomalin LE, Schultz G, et al. Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature. PLoS One. 2018;13:e0203672.
Braunberger TL, Nartker NT, Nicholson CL, et al. Ertapenem - a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa. Int J Dermatol. 2018;57:1088-1093.
Join-Lambert O, Coignard-Biehler H, Jais JP, et al. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients. J Antimicrob Chemother. 2016;71:513-520.
Giamarellos-Bourboulis EJ, Argyropoulou M, Kanni T, et al. Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab. Br J Dermatol. 2020;183:176-178.
Giamarellos-Bourboulis EJ, Prens EP, Habel M, et al. Complement split product C5a is elevated in moderate and severe hidradenitis suppurativa: clinical improvement by targeted therapy coming from the SHINE study. Exp Dermatol. 2021.https://doi.org/10.1111/exd.14342
Global Newswire. ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS), 2020.
Nikolakis G, Stratakis CA, Kanaki T, Slominski A, Zouboulis CC. Skin steroidogenesis in health and disease. Rev Endocr Metab Disord. 2017;17:247-258.
Slominski A, Zbytek B, Nikolakis G, et al. Steroidogenesis in the skin: implications for local immune functions. J Steroid Biochem Mol Biol. 2013;137:107-123.
Sabat R, Chanwangpong A, Schneider-Burrus S, et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One. 2012;7:e31810.
Phan K, Charlton O, Smith SD. Hidradenitis suppurativa and diabetes mellitus: updated systematic review and adjusted meta-analysis. Clin Exp Dermatol. 2019;44:e126-e132.
Kromann CB, Ibler KS, Kristiansen VB, Jemec GBE. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014;94:553-557.
Vilanova I, Hernández JL, Mata C, et al. Insulin resistance in hidradenitis suppurativa: a case-control study. J Eur Acad Dermatology Venereol. 2018;32:820-824.
Evans EA, Sayers SR, Kodji X, et al. Psoriatic skin inflammation induces a pre-diabetic phenotype via the endocrine actions of skin secretome. Mol Metab. 2020;41:101047.
Verdolini R, Clayton N, Smith A, Alwash N, Mannello B. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol. 2013;27:1101-1108.
Jennings L, Hambly R, Hughes R, Moriarty B, Kirby B. Metformin use in hidradenitis suppurativa. J Dermatolog Treat. 2020;31:261-263.
Nikolakis G, Kyrgidis A, Zouboulis CC. Is there a role for antiandrogen therapy for hidradenitis suppurativa? A systematic review of published data. Am J Clin Dermatol. 2019;20:503-513.
Zhou Z, Tang Y, Jin X, et al. Metformin inhibits advanced glycation end products-induced inflammatory response in murine macrophages partly through AMPK activation and RAGE/NF B pathway suppression. J Diabetes Res. 2016;2016:4847812.
Ursini F, Russo E, Pellino G, et al. Metformin and autoimmunity: a “new deal” of an old drug. Front Immunol. 2018;9:1236.
Li W, Ma W, Zhong H, Liu W, Sun Q. Metformin inhibits proliferation of human keratinocytes through a mechanism associated with activation of the MAPK signaling pathway. Exp Ther Med. 2014;7:389-392.
Zheng Z, Chen H, Li J, et al. Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes. 2012;61:217-228.
Esteves CL, Kelly V, Breton A, et al. Proinflammatory cytokine induction of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in human adipocytes is mediated by MEK, C/EBPβ, and NF-κB/RelA. J Clin Endocrinol Metab. 2014;99:E160-E168.
González-López MA, Vilanova I, Ocejo-Viñals G, et al. Circulating levels of adiponectin, leptin, resistin and visfatin in non-diabetics patients with hidradenitis suppurativa. Arch Dermatol Res. 2020;312:595-600.
Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018;9:1048.
Baillie GS. Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases. FEBS J. 2009;276:1790-1799.
Seldon PM, Barnes PJ, Giembycz MA. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes. Cell Biochem Biophys. 1998;29:179-201.
Kwak HJ, Song JS, No ZS, Song JH, Yang SD, Cheon HG. The inhibitory effects of roflumilast on lipopolysaccharide-induced nitric oxide production in RAW264.7 cells are mediated by heme oxygenase-1 and its product carbon monoxide. Inflamm Res. 2005;54:508-513.
Vossen ARJV, van Doorn MBA, van der Zee HH, Prens EP. Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial. J Am Acad Dermatol. 2019;80:80-88.
Aarts P, Vossen ARJV, van der Zee HH, Prens EP, van Straalen KR. Long-term treatment with apremilast in hidradenitis suppurativa: 2-year follow-up of initial responders. J Am Acad Dermatol. 2020:https://doi.org/10.1016/j.jaad.2020.08.113
Sabat R, Grütz G, Warszawska K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010;21:331-344.
Wolk K, Döcke W, von Baehr V, Volk H, Sabat R. Comparison of monocyte functions after LPS- or IL-10-induced reorientation: importance in clinical immunoparalysis. Pathobiology. 1999;67:253-256.
Lingnau M, Höflich C, Volk HD, Sabat R, Döcke WD. Interleukin-10 enhances the CD14-dependent phagocytosis of bacteria and apoptotic cells by human monocytes. Hum Immunol. 2007;68:730-738.
Fukunaga R, Seto Y, Mizushima S, Nagata S. Three different mRNAs encoding human granulocyte colony-stimulating factor receptor. Proc Natl Acad Sci USA. 1990;87:8702-8706.
Dwivedi P, Greis KD. Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies. Exp Hematol. 2017;46:9-20.
Sabat R, Jemec GBE, Matusiak Ł, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6:18.
Wolk K, Brembach TC, Šimaitė D, et al. Activity and components of the granulocyte colony-stimulating factor pathway in hidradenitis suppurativa. Br J Dermatol. 2021:https://doi.org/10.1111/bjd.19795
Witte-Händel E, Wolk K, Tsaousi A, et al. The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction. J Invest Dermatol. 2019;139:1294-1305.
Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173:1546-1549.
Kokolakis G, Wolk K, Schneider-Burrus S, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology. 2020;236:421-430.
Bendall LJ, Bradstock KF. G-CSF: from granulopoietic stimulant to bone marrow stem cell mobilizing agent. Cytokine Growth Factor Rev. 2014;25:355-367.
Zouboulis CC. Adalimumab for the treatment of hidradenitis suppurativa/acne inversa. Expert Rev Clin Immunol. 2016;12:1015-1026.
Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab treatment of hidradenitis suppurativa. N Engl J Med. 2016;375:422-434.
Zouboulis CC, Okun MM, Prens EP, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extention study. J Am Acad Dermatol. 2019;80:60-69.
Zouboulis CC, Hansen H, Caposiena Caro RD, et al. Adalimumab dose intensification in recalcitrant hidradenitis suppurativa/acne inversa. Dermatology. 2020;236:25-30.